Kantaro’s COVID-19 Tests Get CE Mark

Kantaro Biosciences has earned a CE mark certification for two COVID-19 antibody tests, COVID-SeroKlir and COVID-SeroIndex.

The SeroKlir test is designed for use in clinical settings, while the SeroIndex test is intended for use in research and vaccine development.  The quantitative antibody test kits detect the presence or absence of COVID-19 antibodies and measure the level of antibodies a person has produced.

Both tests are certified for use in authorized clinical testing laboratories and do not require any proprietary equipment, the company said.

Kantaro Biosciences is a joint venture of the Mount Sinai Health System and RenalytixAI.